 NEW YORK, March 04, 2021 GLOBE NEWSWIRE -- TG Therapeutics, Inc. NASDAQ: TGTX, today announced that results of the ULTIMATE I II Phase 3 trials evaluating ublituximab, the Companys novel, glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of multiple sclerosis RMS have been selected for presentation at the upcoming American Academy of Neurology AAN annual meeting, being held virtually April 17 22, 2021. The abstract is available online and can be accessed via the below link or on the AAN meeting website at 